Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Skin sensitisation (OECD 442C): negative

Skin sensitisation (OECD 442D): negative

Skin sensitisation (OECD 442E): positive

WoE conclusion from in vitro skin sensitisation battery: not skin sensitising

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records

Referenceopen allclose all

Endpoint:
skin sensitisation: in chemico
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
27 Jun - 14 Jul 2016
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
Version / remarks:
2015
Deviations:
yes
Remarks:
No information on stability, precision and co-elution controls provided. No information on stability/solubility of test substance after preparation of peptide depletion samples and after 22 h incubation.
GLP compliance:
yes (incl. QA statement)
Remarks:
THE DEPARTMENT OF HEALTH OF THE GOVERNMENT OF THE UNITED KINGDOM
Type of study:
direct peptide reactivity assay (DPRA)
Details on the study design:
TEST METHOD
The DPRA is an in chemico test system proposed to address the molecular initiating event of the skin sensitisation adverse outcome pathway, namely protein reactivity, by substance towards model synthetic peptides containing either lysine or cysteine. The DPRA quantifies the free concentration of cysteine- or lysine-containing peptide following incubation with the test substance. Relative peptide concentration is measured by HPLC with gradient elution and UV detection at 220 nm. Cysteine- and lysine peptide percent depletion values are then calculated and used in the prediction model which allows assigning the test substance to one of four reactivity classes used to support the discrimination between sensitisers and non-sensitisers.

TEST SYSTEM
- Supplier: AnaSpec
- Synthetic cysteine-containing peptide:
Alternative name: Ac-RFAACAA-OH
Batch number: 1556171
Molecular weight: 751.5 g/mol
Purity: 95%
Expiry date: 5 years
- Synthetic lysine-containing peptide:
Alternative name: Ac-RFAAKAA-OH
Batch number: 1556172
Molecular weight: 776 g/mol
Purity: 90 - 95%
Expiry date: 5 years

SOLVENT CONTROL AND ASSESSMENT OF TEST ITEM SOLUBILITY
- Solvent: acetonitrile
The solubility of the test item in acetonitrile was assessed at a concentration of 100 mM.

POSITIVE CONTROL
- Substance: cinnamic aldehyde
- Batch number: MKBR2427V
- Purity: >95%
- Expiry date: Feb 2019
The positive control was prepared at a concentration of 100 mM.

STABILITY AND PRECISION CONTROL
Stability and precision controls of both peptides were prepared at a concentration of 0.5 mM.

PEPTIDE STOCK SOLUTION PREPARATION
Cysteine-containing peptide:
- Solvent: phosphate buffer (pH 7.5)
- Concentration: 0.667 mM
Lysine-containing peptide:
- Solvent: ammonium acetate buffer (pH 10.2)
- Concentration: 0.667 mM

INCUBATION CONDITIONS OF THE TEST SUBSTANCE WITH THE PEPTIDE SOLUTIONS
- Peptide to test substance ratios: Cysteine-containing peptide: 1:10 (0.5 mM peptide, 5 mM test substance/positive control); Lysine-containing peptide: 1:50 (0.5 mM peptide, 25 mM test substance/positive control)
- Temperature used during treatment / exposure: 25 °C
- Duration of treatment / exposure: at least 22 h prior to initiation of the analysis run

NUMBER OF REPLICATES
for each peptide in triplicates for treatment and control

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
- Specification of the device: Waters Alliance 2695 separation module and 2487 dual wavelength detector
- Column: Agilent Zorbax SB C18, 3.5 µm, 100 x 2.1 mm with guard column Phenomenex AJO4286
- HPLC mobile phase:
A: 0.1% (v/v) trifluoracetic acid in deionised water
B: 0.085% (v/v) trifluoracetic acid in acetonitrile
- Flow: 0.35 mL/min
- Gradient:
Time (min): 0, 20, 21, 23, 23.5, 30
% A: 90, 75, 10, 10, 90, 90
% B: 10, 25, 90, 90, 10, 10
- Detector Wavelength: 220 nm
- Calibration standard concentrations of both peptides: 0.0167, 0.0334, 0.0667, 0.133, 0.267 and 0.534 mM
- Column temperature: 30 °C
Key result
Run / experiment:
other: ≥ 22 h incubation
Parameter:
other: % depletion of cysteine-containing peptide
Remarks:
(mean value of 3 replicates)
Value:
11.5 %
Vehicle controls validity:
valid
Negative controls validity:
not applicable
Positive controls validity:
valid
Key result
Run / experiment:
other: ≥ 22 h incubation
Parameter:
other: % depletion of lysine-containing peptide
Remarks:
(mean value of 3 replicates)
Value:
0.323 %
Vehicle controls validity:
valid
Negative controls validity:
not applicable
Positive controls validity:
valid
Key result
Run / experiment:
other: ≥ 22 h incubation
Parameter:
other: % overall mean depletion
Value:
5.89 %
Vehicle controls validity:
not applicable
Negative controls validity:
not applicable
Positive controls validity:
not applicable
Other effects / acceptance of results:
TEST-SPECIFIC CONFOUNDING FACTORS
- Other confounding effects: No co-elution of the test substance occurred during the assay. The solubility of the test substance in acetonitrile at a nominal concentration of 100 mM was confirmed.

ACCEPTANCE OF RESULTS:
All analytical acceptance criteria for each peptide were met.

Table 5. Mean peptide depletion of cysteine-containing peptide.

 

 

Peak area (µV.sec)

Peptide concentration

(µg/mL)*

Peptide depletion (%)**

Mean depletion ± CV (%)

 

Positive control

279682

109.54

70.5

69.7 ± 2.41

291615

114.65

69.3

291759

114.72

69.3

 

Test substance

865374

360.39

8.84

11.5 ± 2.78

819108

340.58

13.7

836963

348.22

11.8

 CV: Coefficient of Variation

*: Samples prepared at a concentration of 376 μg/mL (0.5 mM)

**: Calculated against a mean reference control peak area of 949240 μV.sec (n=6)

Table 6. Mean peptide depletion of lysine-containing peptide.

 

 

Peak area (µV.sec)

Peptide concentration

(µg/mL)*

Peptide depletion (%)**

Mean depletion ± CV (%)

 

Positive control

314190

156.37

59.7

58.4 ± 3.22

324364

161.47

58.4

335094

166.84

57.0

 

Test substance

789061

394.31

- 1.14

0.32 ± 1.31

769581

384.55

1.36

774347

386.94

0.75

CV: Coefficient of Variation

*: Samples prepared at a concentration of 388 μg/mL (0.5 mM)

**: Calculated against a mean reference control peak area of 780180 μV.sec (n=6)                            

Interpretation of results:
other: DPRA prediction: negative (no or minimal reactivity) according to OECD 442C
Conclusions:
Under the conditions of the Direct Peptide Reactivity Assay the test substance showed no or minimal peptide reactivity.
Executive summary:

Protein reactivity of the test substance was determined in a Direct Peptide Reactivity Assay (DPRA) according to OECD Guideline 442C and in compliance with GLP (2017). The overall mean percent cysteine and lysine depletion is 5.89% and therefore the test substance showed no or minimal peptide reactivity (mean % depletion ≤ 6.38%).

Endpoint:
skin sensitisation: in vitro
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
09 - 25 Nov 2016
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 442D (In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method)
Version / remarks:
adopted 4 Feb 2015
Deviations:
no
GLP compliance:
yes (incl. QA statement)
Remarks:
Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, Schwabach, Germany
Type of study:
activation of keratinocytes
Details on the study design:
TEST METHOD
The in vitro KeratinoSens™ assay enables detection of the sensitising potential of a test substance by addressing the second molecular key event of the Adverse Outcome Pathway (AOP), namely activation of keratinocytes, by quantifying the luciferase activity in the transgenic cell line KeratinoSens™. The luciferase activity, assessed by luminescence measurement, compared to the respective solvent controls is used to support discrimination between skin sensitiser and non-sensitisers.

TEST CELL LINE
- Type: KeratinoSens™
- Source: Givaudan, Switzerland
- Passage number: 3 (Experiment 1), 5 (Experiment 2)

CELL CULTURE CONDITIONS
- Type and identity of media:
Maintenance medium: Dulbecco’s Modified Eagle Medium (GlutaMAX™) supplemented with 1.0 g/L D-glucose and Na-pyruvate, 10% fetal bovine calf serum and 1% geneticin (final concentration 500 µg/mL)
Assay medium: Dulbecco’s Modified Eagle Medium (GlutaMAX™) supplemented with 1.0 g/L D-glucose and Na-pyruvate and 10% fetal bovine calf serum
Test substance exposure medium: Dulbecco’s Modified Eagle Medium (GlutaMAX™) supplemented with 1.0 g/L D-glucose and Na-pyruvate and 1% fetal bovine calf serum
- Temperature (°C): 37 ± 1.0
- CO2 (%): 5.0

TEST CONCENTRATIONS
0.98, 1.95, 3.91, 7.81, 15.63, 31.25, 61.5, 125, 250, 500, 1000 and 2000 µM

CONTROLS
Vehicle control
- Substance: dimethyl sulfoxide (DMSO)
- Final concentration: 1% (v/v)
Positive control
- Substance: cinnamic aldehyde
- Final concentration: 4 - 64 µM

EXPOSURE CONDITIONS
- Exposure duration: 48 ± 1 h

NUMBER OF REPLICATIONS: triplicates in two independent experiments (treatment group, positive control); sextuplicates in two independent experiments (vehicle control)

DETERMINATION OF CELL VIABILITY
- Method: MTT assay
- MTT concentration: 5 mg/mL
- Incubation time: 4 h
- Device: plate reader
- Wavelength: 600 nm

DETERMINATION OF LUMINESCENCE
- Cell lysis reagent: Luciferase Cell Culture Lysis 5x Reagent Kit (Promega, Cat. No. E1531, Lot No. 0000199324)
- Luciferase reagent: Luciferase Assay Kit (Promega, Cat. no. E1501, Lot No. 0000211803)
- Device: plate reader
Key result
Run / experiment:
other: Experment 1
Parameter:
other: maximum luciferase acitivity induction (Imax)
Value:
1.34
Vehicle controls validity:
valid
Negative controls validity:
not applicable
Positive controls validity:
valid
Remarks on result:
other: test item concentration: 2000 µM; cell viability: 101.7%
Key result
Run / experiment:
other: Experiment 2
Parameter:
other: maximum luceferase activity induction (Imax)
Value:
1.2
Vehicle controls validity:
valid
Negative controls validity:
not applicable
Positive controls validity:
valid
Remarks on result:
other: test item concentration: 2000 µM; cell viability: 106.5%
Other effects / acceptance of results:
ADDITIONAL INFORMATION ON CYTOTOXICITY: No evidence of cytotoxicity (cell viability < 70%) was observed.

ACCEPTANCE OF RESULTS:
- Acceptance criteria met for vehicle control: The average coefficient of variation of the luminescence reading for the vehicle control was < 20% (15.2% and 9.6% in Experiment 1 and 2, respectively).
- Acceptance criteria met for positive control: The luciferase activity induced by the positive control at a concentration of 64 µM was between 2 and 8 (3.97 and 2.73 in Experiment 1 and 2, respectively) and the calculated EC1.5 value was between 7 and 30 µM (11.12 and 25.69 µM in Experiment 1 and 2, respectively).

Table 2. Results of the cytotoxicity measurement

 

Concentration [µM]

Cell viability [%]

 

 

Experiment 1

Experiment 2

Mean ± SD

Vehicle control

100.0

100.0

100.0 ± 0.0

 

 

Positive control

4

105.6

104.5

105.1 ± 0.8

8

109.3

103.7

106.5 ± 4.0

16

113.3

114.1

113.7 ± 0.5

32

120.4

127.3

123.9 ± 4.9

64

119.8

120.7

120.3 ± 0.7

 

 

 

 

 

Test substance

0.98

97.2

120.5

108.8 ± 16.5

1.95

104.3

107.2

105.8 ± 2.1

3.91

105.8

113.6

109.7 ± 5.5

7.81

106.0

118.2

112.1 ± 8.6

15.63

105.2

112.6

108.9 ± 5.2

31.25

106.4

121.3

113.8 ± 10.6

62.50

99.9

114.7

107.3 ± 10.5

125

104.2

109.7

107.0 ± 3.9

250

104.8

115.1

109.9 ± 7.3

500

107.6

115.9

111.7 ± 5.9

1000

102.3

107.4

104.8 ± 3.6

2000

101.7

106.5

104.1 ± 3.4

 Table 3. Induction of luciferase activity

 

Concentration [µM]

Fold induction

 

 

Experiment 1

Experiment 2

Mean ± SD

Vehicle control

1.0

1.0

1.0 ± 0.0

 

 

Positive control

4

1.29

1.17

1.23 ± 0. 09

8

1.24

1.14

1.19 ± 0.07

16

1.90

1.37

1.64 ± 0.37

32

2.06

1.58

1.82 ± 0.33

64

3.97

2.73

3.35 ± 0.88

 

 

 

 

 

Test substance

0.98

1.06

0.98

1.02 ± 0.06

1.95

0.98

0.97

0.97 ± 0.01

3.91

0.95

1.02

0.99 ± 0.05

7.81

0.98

0.98

0.98 ± 0.0

15.63

0.93

0.93

0.93 ± 0.0

31.25

1.02

0.99

1.00 ± 0.02

62.50

1.05

0.95

1.00 ± 0.07

125

1.00

0.98

0.99 ± 0.01

250

0.97

0.92

0.95 ± 0.04

500

1.01

1.02

1.01 ± 0.0

1000

1.08

0.97

1.02 ± 0.08

2000

1.34

1.20

1.27 ± 0.10

 

Interpretation of results:
other: activation of keratinocytes negative
Remarks:
according to OECD 442D
Conclusions:
Under the conditions of the ARE-Nrf2 Luciferase test the test substance did not induce luciferase activity in the transgenic KeratinoSens™ cell line.
Executive summary:

In two independent experiments, a max luciferase activity induction (Imax) of 1.34 and 1.20 was determined at a concentration of 2000 µM, respectively. The corresponding cell viabilities were 101.7% and 106.5%, respectively. Therefore, in this study the test substance did not induce luciferase activity in the transgenic KeratinoSens™ cell line.

Endpoint:
skin sensitisation: in vitro
Type of information:
experimental study
Adequacy of study:
key study
Study period:
13 Jun - 1 Jul 2016
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
other: Draft OECD Guideline 442E (In Vitro Skin Sensitisation: human Cell Line Activation Test)
Version / remarks:
December 2015
Deviations:
yes
Remarks:
cytotoxicity measurement and estimation of the CV75 value was performed by XTT test instead of flow cytometry
GLP compliance:
yes (incl. QA statement)
Remarks:
Hess. Ministerium für Umwelt, Klimaschutz, Landwirtschaft und Verbraucherschutz, Wiesbaden, Germany
Type of study:
activation of dendritic cells
Details on the study design:
TEST CELL LINE
- Strain: THP-1 cells (human monocytic leukemia cell line)
- Source: American Type Culture Collection
- Passage number: 4 (XTT test); 11 (h-CLAT)

CELL CULTURE CONDITIONS
- Type and identity of media: RPMI-1640 supplemented with 10% (v/v) FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.05 mM 2-mercaptoethanol, 4.5 g/L glucose, 1% (v/v) pyruvate and 1% (v/v) L-glutamine
- Temperature (°C): 37 ± 1.5
- CO2 (%): 5.0 ± 0.5

DOSE FINDING ASSAY BY CYTOTOXICITY MEASUREMENT (XTT TEST)
The doses investigated in the main experiment (h-CLAT) were determined with a XTT test. The XTT test is a method to investigate the cytotoxicity of a test substance. The test is based on the cleavage of the yellow tetrazolium salt, sodium 3'-(1-phenylaminocarbonyl)-(3,4-tetrazolium)-bis-(4–methoxy-6-nitro)-benzenesulfonic acid hydrate (XTT), to form an orange water soluble formazan dye by dehydrogenase activity in active mitochondria. Two independent cytotoxicity experiments were performed with different cell cultures to obtain a reliable concentration showing 75% cell viability (CV75).

CONTROLS
Negative Control
- Substance: culture medium
Vehicle control
- Substance: dimethyl sulfoxide (DMSO)
- Concentration: 0.2 - 0.5%

EXPOSURE CONDITIONS
- Exposure duration: 24 ± 1 h

TEST CONCENTRATIONS
- Justification for top dose: The test substance was soluble in DMSO up to and including 125 µg/mL as tested by a solubility test.
0.98, 1.96, 3.91, 7.81, 15.63, 31.25, 62.5 and 125 µg/mL

NUMBER OF REPLICATIONS: quadruplicates per concentration in two independent experiments

MEASUREMENT
- Device: microplate reader (Versamax Molecular Devices)
- Wavelength: 450 nm
- Reference wavelength: 690 nm

EVALUATION CRITERIA
A decrease in number of living cells results in a decrease in the overall activity of mitochondrial dehydrogenases in the sample. This decrease directly correlates to the amount of orange formazan formed, as monitored by the absorbance. The relative absorbance as compared to the solvent control is calculated using the formula:
Relative absorbance = 100 x [(mean absorbance test substance) - (absorbance blank)] / [(mean absorbance vehicle control) - (absorbance blank)]

To calculate the concentration of test substance needed to reduce the relative absorbance to 75% of the vehicle control (CV75) the following formula is used:
CV75 = Conc. > 75 - ([(Conc. > 75) - (Conc. < 75)] x [(% > 75) - 75] / [(% > 75) - (% < 75)])
a) Conc. > 75: max. measured concentration with the % of vehicle control > 75%
b) Conc. < 75: min. measured concentration with the % of vehicle control < 75%
c) % > 75: relative absorbance at a) in %
d) % < 75: relative absorbance at b) in %

ACCEPTANCE CRITERIA
The XTT test is considered to be acceptable if it meets the following criteria:
- mean absorbance of the negative control is ≥ 0.5
- mean viability of the vehicle control is ≥ 70%


h-CLAT (main study)
The h-CLAT method is an in vitro method which quantifies changes of cell surface marker expression (CD86 and CD54) on a human cell line, THP-1 cells, following 24 h exposure to the test substance. The changes of surface marker expression are measured by flow cytometry following cell staining with fluorescein isothiocyanate (FITC)-labelled antibodies. The relative fluorescence intensity of surface markers compared to vehicle control are calculated and used in the prediction model to support the discrimination between sensitisers and non-sensitisers.

CONTROLS
Negative control
- Substance: culture medium
Vehicle control
- Substance: dimethyl sulfoxide (DMSO)
- Concentration: 0.2%
Positive control
- Substance: 2,4-dinitrochlorobenzene (DNCB) in DMSO
- Concentration: 2 and 3 µg/mL

EXPOSURE CONDITIONS
- Exposure duration: 24 ± 1 h

TEST CONCENTRATIONS
- Justification for top dose: Since a CV75 value could not be determined in the XTT test, the highest soluble test substance concentration was multiplied with 1.2 (150 µg/mL). Due to a calculation error the highest test substance concentration used was 300 μg/mL instead of 150 μg/mL.
83.7, 100.5, 120.6, 144.7, 173.6, 208.2, 250 and 300 µg/mL

NUMBER OF REPLICATIONS: at least in triplicates for the different stainings in two independent experiments

STAINING
- Antibodies: FITC anti-CD54 (Clone: Fun-1); FITC anti-CD86 (Clone: 6.5B5); FITC mouse IgG1 (isotype control)
- Temperature: 2 - 8 °C
- Duration: 30 ± 5 min

MEASUREMENT
- Device: flow cytometer FACSCalibur (Becton Dickinson)

EVALUATION CRITERIA
The relative fluorescence intensity (RFI) is used as an indicator of CD86 and CD54 expression, and is calculated as follows for each concentration:
RFI (%) = [(MFI of test substance treated cells) - (MFI of test substance treated isotype control cells) / (MFI of vehicle control cells) - (MFI of vehicle isotype control cells)] x 100
MFI: geometric mean fluorescence intensity (GeoMean)

The cell viability is calculated as follows for each concentration:
Cell viability (%) = (mean cytotox of vehicle control cells) / (mean cytotox of test substance treated cells) x 100
Where the mean cytotox is the mean of GeoMean (7-AAD) isotype control, GeoMean (7-AAD) CD54 and GeoMean (7-AAD) CD86.

The test substance is tested in 2 independent runs. If the RFI of CD86 is ≥ 150% or if the RFI of CD54 is ≥ 200% in both independent run data, the test substance is considered to be a sensitizer. Otherwise it is considered to be a non-sensitizer. In case of different results in both runs, a third run has to be performed. If the RFI of CD86 is ≥ 150% at any dose in at least 2 of 3 independent run data, or if the RFI of CD54 is ≥ 200% in at least 2 of 3 independent run data, the test substance is considered to be a sensitizer. Otherwise it is considered to be a non-sensitizer.

ACCEPTANCE CRITERIA
The study is considered as valid, if the following criteria are met:
- Cell viability of negative control is adjusted to 100% and the cell viability of the vehicle control should be more than 90% in comparison to the negative control.
- In the positive control, RFI values of both CD86 and CD54 should exceed the positive criteria (CD86 ≥ 150% and CD54 ≥ 200%) and the cell viability should be > 50%.
- In the vehicle control, RFI values compared to the negative control of both CD86 and CD54 should not exceed the positive criteria (CD86 ≥ 150% and CD54 ≥ 200%).
- For negative and vehicle controls, the MFI ratio of CD86 and CD54 to isotype control should be > 105%.
- For the test substance resulting in negative outcome, the cell viability at the 1.2 × CV75 value should be less than 90%. If the cell viability at the 1.2 × CV75 value is more than 90% for a positive tested test substance, the data will be acceptable. If 5 mg/mL in saline, 1 mg/mL in DMSO or the highest soluble dose will be used as the maximal test concentration instead of CV75-based dose, the data for test substance are accepted independent by the cell viability.
- The cell viability of at least 4 doses in each experiment should be ≥50%.
Key result
Run / experiment:
other: 24 h incubation
Parameter:
other: relative fluorescence intensity of CD54 (%)
Value:
200
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Remarks on result:
other: in 2 independent runs
Key result
Run / experiment:
other: 24 h incubation
Parameter:
other: relative fluorescence intensity of CD86 (%)
Value:
150
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Remarks on result:
other: in 2 independent runs
Other effects / acceptance of results:
ADDITIONAL INFORMATION ON CYTOTOXICITY:
XTT test
Cytotoxic effects were not observed following incubation with the test substance up to the highest soluble concentration (125 µg/mL). The viability of the cells spaced within a range of 93.05 to 115.64% in the first experiment and within a range of 89.48 to 111.90% in the second experiment (threshold of cytotoxicity: < 75%). Due to the lack of cytotoxicity, a CV75 value could not be calculated.
h-CLAT
The cell viability was not negatively affected (viability > 95%) in both independent experiments.

ACCEPTANCE OF RESULTS:
- Acceptance criteria met for vehicle control: In the vehicle control, RFI values compared to the negative control of both CD86 and CD54 did not exceed the positive criteria (CD86 ≥150% and CD54 ≥200%).
- Acceptance criteria met for positive control: The RFI values of the positive control for CD86 and CD54 exceeded the positive criteria (CD86 >150% and CD54 >200%) and the cell viability was >50%.

Table 1: Results of the first XTT test

 

Concentration [µg/mL]

Mean absorbance*

Blank

Absorbance in % of vehicle control**

Negative control

-

0.799 ± 0.026

0.274

97.20

Vehicle control

-

0.804 ± 0.024

0.264

100.00

Test substance

0.98

0.773 ± 0.034

0.259

95.28

1.96

0.785 ± 0.032

0.260

97.32

3.91

0.780 ± 0.039

0.262

95.87

7.81

0.727 ± 0.023

0.221

93.71

15.63

0.762 ± 0.019

0.259

93.05

31.25

0.823 ± 0.108

0.255

105.08

62.5

0.813 ± 0.034

0.256

103.00

125

0.879 ± 0.063

0.254

115.64

*: mean absorbance (absolute) of 4 wells

**: relative absorbance

 

Table 2: Results of the second XTT test

 

Concentration [µg/mL]

Mean absorbance*

Blank

Absorbance in % of vehicle control**

Negative control

-

0.784 ± 0.005

0.265

99.11

Vehicle control

-

0.795 ± 0.030

0.271

100.00

Test substance

0.98

0.739 ± 0.013

0.265

90.43

1.96

0.762 ± 0.014

0.261

95.62

3.91

0.730 ± 0.023

0.261

89.48

7.81

0.783 ± 0.031

0.267

98.43

15.63

0.781 ± 0.008

0.265

98.54

31.25

0.756 ± 0.019

0.264

93.88

62.5

0.771 ± 0.014

0.261

97.38

125

0.848 ± 0.043

0.262

111.90

*: mean absorbance (absolute) of 4 wells

**: relative absorbance

Table 3. Results of the first h-CLAT run

 

Concentration [µg/mL]

Antibody / ISO

MFI GeoMean (FITC)

MFI - ISO

Csto(Geo) GeoMean (7-AAD)

Mean Cyto

RFI (%)

Viability (%)

Negative control

-

ISO

2.34

-

2.13

2.0

-

100.0

CD54

2.82

0.48

2.08

100.0

CD86

3.41

1.07

1.90

100.0

Vehicle control

-

ISO

2.36

-

2.22

2.0

-

100.0

CD54

2.89

0.53

1.99

100.0

CD86

3.62

1.26

1.81

100.0

Positive control

2

ISO

3.06

-

2.82

2.3

-

86.1

CD54

6.80

3.74

2.25

705.7*

CD86

8.51

5.45

1.92

432.5*

3

ISO

3.09

-

3.03

2.3

-

87.9

CD54

9.70

6.61

1.95

1247.2*

CD86

9.44

6.35

1.87

504.0*

Test substance

83.7

ISO

2.61

-

2.34

2.1

-

97.3

CD54

4.45

1.84

1.91

347.2*

CD86

3.86

1.25

1.94

99.2

100.5

ISO

2.75

-

2.41

2.1

-

95.4

CD54

4.80

2.05

1.96

386.8*

CD86

4.27

1.52

1.94

120.6

120.6

ISO

2.80

-

2.45

2.1

-

96.2

CD54

5.62

2.82

1.91

532.1*

CD86

4.54

1.74

1.90

138.1

144.7

ISO

2.69

-

2.17

1.8

-

110.7

CD54

6.71

4.02

1.64

758.5*

CD86

5.34

2.65

1.63

210.3*

173.6

ISO

2.89

-

2.22

1.9

-

107.5

CD54

7.79

4.90

1.66

924.5*

CD86

5.37

2.48

1.72

196.8*

208.3

ISO

3.04

-

2.50

1.9

-

103.6

CD54

11.33

8.29

1.68

1564.2*

CD86

6.68

3.64

1.63

288.9*

250

ISO

3.45

-

2.34

1.9

-

108.3

CD54

13.01

9.56

1.62

1803.8*

CD86

8.13

4.68

1.60

371.4*

300

ISO

3.08

-

2.74

2.1

-

96.3

CD54

14.80

11.72

1.72

2211.3*

CD86

7.64

4.56

1.79

361.9*

*: RFI value of CD86 or CD54 exceeded the criteria for a positive response (CD86 ≥ 150% and CD54 ≥ 200%).

 

Table 4. Results of the second h-CLAT run

 

Concentration [µg/mL]

Antibody / ISO

MFI GeoMean (FITC)

MFI - ISO

Csto(Geo) GeoMean (7-AAD)

Mean Cyto

RFI (%)

Viability (%)

Negative control

-

ISO

2.28

 -

2.35

2.2

 -

100.0

CD54

2.94

0.66

2.19

100.0

CD86

3.86

1.58

1.98

100.0

Vehicle control

-

ISO

2.22

 -

2.39

2.1

- 

100.0

CD54

2.96

0.74

2.24

100.0

CD86

4.09

1.87

1.52

100.0

Positive control

2

ISO

2.42

 -

2.78

2.4

 -

87.2

CD54

7.23

4.81

2.29

650.0*

CD86

6.42

4.00

1.98

213.9*

3

ISO

2.61

 -

3.25

2.3

 -

89.8

CD54

8.83

6.22

1.83

840.5*

CD86

9.39

6.78

1.77

362.6*

Test substance

83.7

ISO

2.34

- 

2.42

2.1

 -

100.0

CD54

4.74

2.40

1.89

324.3*

CD86

4.34

2.00

1.84

107.0

100.5

ISO

2.35

 -

2.39

2.0

- 

102.2

CD54

5.14

2.79

1.81

377.0*

CD86

4.52

2.17

1.82

116.0

120.6

ISO

2.45

 -

2.46

2.0

- 

103.2

CD54

6.70

4.25

1.69

574.3*

CD86

4.75

2.30

1.81

123.0

144.7

ISO

2.57

 -

2.48

2.1

- 

97.3

CD54

8.01

5.44

1.68

735.1*

CD86

4.43

1.86

2.16

99.5

173.6

ISO

2.49

 -

2.59

2.1

- 

98.6

CD54

10.61

8.12

1.60

1097.3*

CD86

4.75

2.26

2.05

120.9

208.3

ISO

2.48

 -

2.61

2.0

- 

103.4

CD54

14.71

12.23

1.47

1652.7*

CD86

5.09

2.61

1.87

139.6

250

ISO

2.43

 -

2.61

1.9

- 

105.7

CD54

19.27

16.84

1.39

2275.7*

CD86

5.61

3.18

1.82

170.1*

300

ISO

2.44

 -

2.63

1.9

 -

105.9

CD54

17.12

14.68

1.41

1983.8*

CD86

5.65

3.21

1.77

171.7*

*: RFI value of CD86 or CD54 exceeded the criteria for a positive response (CD86 ≥150% and CD54 ≥200%).

Interpretation of results:
other: activation of dendritic cells positive according to OECD 442E
Conclusions:
Under the conditions of the Human Cell Line Activation Test the test substance increased the expression of both cell surface markers, CD54 and CD86, which is associated with the process of activation of monocytes and dendritic cells. Based on this result, the h-CLAT prediction is considered positive for skin sensitisation.
Executive summary:

The test substance increased the expression of cell surface marker CD54 and CD86 to greater than 200% and 150%, respectively in two independent experiments. Thus, the h-CLAT prediction for activation of dendritic cells is considered positive.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (not sensitising)

Respiratory sensitisation

Endpoint conclusion
Endpoint conclusion:
no study available
Additional information:

Protein reactivity of the test substance was dertermined in a Direct Peptide Reactivity Assay (DPRA) according to OECD Guideline 442C and in compliance with GLP (2017). The overall mean percent cystein and lysine depletion is 5.89% and therefore the test substance showed no or minimal peptide reactivity (mean % depletion ≤ 6.38%).

In a second study, the activation of keratinocytes of keratinocytes of the test substance was investigated in an ARE-Nrf2 Luciferase Test (LuSens) in the transgenic KeratinoSens™ cell line according to OECD Guideline 442D and in compliance with GLP (2017). In two independent experiments, a max luciferase activity induction (Imax) of 1.34 and 1.20 was determined at a concentration of 2000 µM, respectively. The corresponding cell viabilities were 101.7% and 106.5%, respectively. Therefore, in this study the test substance did not induce luciferase activity in the transgenic KeratinoSens™ cell line.

In a third study, dendritic cell response of the test substance was investigated by a Human Cell Line Activation Test (h-CLAT) according to OECD Guideline 442E and in compliance with GLP (2016). The test substance increased the expression of cell surface marker CD54 and CD86 to greater than 200% and 150%, respectively in two independent experiments. Thus, the h-CLAT prediction for activation of dendritic cells is considered positive.

Based on a weight of evidence approach considering one positive and two negative results in the in vitro test battery according to the Adverse Outcome Pat way defined for skin sensitisation, the test substance is not considered to be a skin sensitiser.

Justification for classification or non-classification

The available data on skin sensitisation of the test substance do not meet the criteria for classification according to Regulation (EC) 1272/2008, and are therefore conclusive but not sufficient for classification.